Morphic Therapeutic
Professor Schreiber was born in 1962 and received medical degrees in 1988 at the University of Hamburg. He is a certificated internist and gastroenterologist. Following a postdoctoral research fellowship in the Departments of Gastroenterology at Washington University (St. Louis, MO) and University of Pennsylvania (Philadelphia, PA) he became junior Faculty in the Department of Gastroenterology at the Charité University Hospital in Berlin, Germany. In 1996 he assumed the position of an associated professor in the Hospital for General Internal Medicine at the University Hospital Schleswig-Holstein (UKSH), Kiel University, Germany.
Stefan Schreiber´s present position is a Full Professor of Medicine. He is the director of the Department of Internal Medicine I and head of the Institute of Clinical Molecular Biology, both at Kiel University. Moreover, he is the speaker of the German DFG cluster of excellence “Precision Medicine in Chronic Inflammation”, PMI.
His research interests include the molecular genetics and pathophysiology of chronic intestinal inflammation, the clinical development of new therapies for IBD, and the discovery of mechanisms that control ageing. Memberships in professional societies include the American Gastroenterological Association, the European Society of Clinical Investigation, the Scientific Committee of the German Crohn’s and Colitis Foundation, the German Society for Internal Medicine, and the German Society for Gastrointestinal and Metabolic Disorders. Professor Schreiber has been an invited lecturer and held chairmanships at multiple national and international meetings. He is a joint editor of some famous international journals in IBD and genetics and has to his credit more than 1000 original publications in different leading scientific journals.
This person is not in the org chart
This person is not in any offices
Morphic Therapeutic
1 followers
Morphic Therapeutic is leading the development of a new generation of oral integrin drugs, informed by decades of world-leading expertise and a unique integrin discovery platform.